drugset / Trial / NCT05148481
A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of BIIB104 in healthy Japanese and non-Japanese participants. The secondary objective of the study is to evaluate the safety and tolerability of multiple, oral doses of BIIB104 administered twice daily (BID) for 9 days, with an additional dose occurring in the morning on Day 10 in healthy Japanese and non-Japanese participants.
Timeline
- Start
- 2021-11-23
- Primary completion
- 2022-01-30
- Completion
- 2022-02-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PESAMPATOR | Small molecule | — | Oral |
Indications
No indication recorded.